The availability of scientific and executive management talent and the access to later-stage investment capital remain major issues for Michigan’s life sciences industry. That capital gap is worst when it comes to securing large financing rounds from in-state sources for life sciences companies that were seeded years ago and have moved down the product development pathway, according to industry professionals MiBiz gathered for an executive roundtable discussion.
The Capabilities Matrix shows the depth of expertise across our membership. We are able to fulfill any need along the product development life cycle.
VIEW CAPABILITIES MATRIX
Be part of an open, collaborative environment and discover best practices for clinical research, medical device production, and research and development.